The results (Fig. 1A) indicated that both TAM (CD68/CD163 positive) recruitment and VM (PAS positive/CD31 negative) were significantly enhanced in RCC tissues of patients in stage III and stage IV compared with those in stages I and II (Fig. 1B, C). This evidence concerns the gene CD163 and renal cell carcinoma.